证券代码：002589 证券简称：瑞康医药 公告编号：2025-040 瑞康医药集团股份有限公司 董 事 会 关于公司董事、董事会秘书及副总裁解除留置 2025 年 8 月 13 日 并变更为责令候查的公告 敬请广大投资者理性投资，注意投资风险。 特此公告。 瑞康医药集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）于 2025 年 7 月 3 日披露 了《关于公司董事、董事会秘书及副总裁被采取留置措施的公告》（公告编号： 2025-037），公司董事、董事会秘书及副总裁李喆先生被实施留置措施。 公司于 2025 年 8 月 12 日收到济南市济阳区监察委员会签发的《变更留置通 知书》，济南市济阳区监察委员会已解除对李喆先生的留置措施，变更为责令候 查措施。目前公司生产经营情况正常，李喆先生能够正常履行董事、董事会秘书 及副总裁职责。 公司指定的信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》、 《证券日报》和巨潮资讯网(http://www.cninfo.com.cn)，公司所有信息均以在 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 一、回购股份的进展情况 证券代码：002589 证券简称：瑞康医药 公告编号：2025-039 截至2025年7月31日，公司通过股份回购专用证券账户以集中竞价方式回购公司股份2,044.6517万股，占 公司目前总股本的1.36%，最高成交价3.08元/股，最低成交价2.75元/股，成交总金额6,039.63万元（不 含交易费用）。本次回购股份符合公司既定的回购股份方案及相关法律法规的要求。 瑞康医药集团股份有限公司 二、其他说明 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于2024年11月7日召开第五届董事会第十 次会议，审议通过了《关于回购公司股份方案的议案》，同意公司使用银行专项贷款资金及自有资金以 集中竞价交易方式回购公司部分已发行的人民币普通股（A股），本次回购股份将用于实施员工持股计 划，回购股份的资金总额不低于人民币10,000万元（含），不超过人民币20,000万元（含），回购股份 的价格不超过人民币4 ...

证券日报网讯 8月5日晚间，瑞康医药发布公告称，截至2025年7月31日，公司通过股份回购专用证券账 户以集中竞价方式回购公司股份2，044.6517万股，占公司目前总股本的1.36%。 （编辑 楚丽君） ...

证券代码：002589 证券简称：瑞康医药 公告编号：2025-039 瑞康医药集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"、"瑞康医药"）于 2024 年 11 月 7 日召开第五届董事会第十次会议，审议通过了《关于回购公司股份方 案的议案》，同意公司使用银行专项贷款资金及自有资金以集中竞价交易方式回 购公司部分已发行的人民币普通股（A 股），本次回购股份将用于实施员工持股 计划，回购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含），回购股份的价格不超过人民币 4.5 元/股（含），具体回购股份的数 量以回购期限届满或回购完毕时实际回购的股份数量为准，实施期限为董事会审 议通过回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 11 月 11 日 在巨潮资讯网披露《第五届董事会第十次会议决议的公告》（2024-036）及《关 于回购公司股份方案暨取得金融机构股票回购专项贷款承诺函的公告》（公告编 号：2024 ...

瑞康医药（SZ 002589，收盘价：3.16元）8月5日晚间发布公告称，截至2025年7月31日，公司通过股份 回购专用证券账户以集中竞价方式回购公司股份约2044.65万股，占公司目前总股本的1.36%，最高成交 价3.08元/股，最低成交价2.75元/股，成交总金额6039.63万元。 2024年1至12月份，瑞康医药的营业收入构成为：药品及器械销售占比98.84%，移动医疗占比0.86%， 租赁占比0.3%。 （文章来源：每日经济新闻） ...

Group 1 - The resignation of Han Chunlin, Vice President of Ruikang Pharmaceutical, is due to personal reasons and will not affect the board's operations or normal business activities [2][4] - Han Chunlin, born in 1993, has been with Ruikang Pharmaceutical since 2013, holding various positions and becoming Vice President in 2023 [3] - His departure adds uncertainty to the company, which is already facing operational pressures, with revenue declining from 27.2 billion in 2020 to 7.97 billion in 2024 [4] Group 2 - Han Chunlin's salary for 2024 was 904,400 yuan, significantly higher than the average of 467,300 yuan for other senior executives [3] - The company has been under pressure, with stock prices consistently below net asset value and previous attempts by the controlling shareholder to transfer shares failing [4] - Ruikang Pharmaceutical, established in 2004, is a leading player in the domestic pharmaceutical distribution sector, involved in drug distribution, medical devices, and digital healthcare [4]

Core Viewpoint - The frequent personnel changes at Ruikang Pharmaceutical are indicative of the company's declining performance, with significant revenue drops and market share losses over recent years [2][5]. Group 1: Company Performance - Ruikang Pharmaceutical's revenue has plummeted from a peak of 35.3 billion yuan in 2019 to 7.966 billion yuan in 2024, representing a decrease of approximately 77% [5]. - The company has fallen from being among the top 10 in the industry to outside the top 20, highlighting a significant decline in its market position [2]. - In 2023, Ruikang ranked 26th among pharmaceutical distribution companies, with major competitors like China National Pharmaceutical, Shanghai Pharmaceutical, and others significantly outperforming it [5]. Group 2: Business Strategy - Following a period of nationwide expansion, Ruikang has initiated a strategy of business contraction, focusing on core markets such as Shandong and Beijing [4]. - The company has been closing and transferring numerous subsidiaries, with 53 and 29 subsidiaries being closed or transferred in 2023 and 2024, respectively [4]. Group 3: Personnel Changes - The resignation of Vice President Han Chunlin and the detention of Secretary Li Zhe by local authorities have raised concerns about the company's governance and operational stability [2][5]. - The company claims that Han's departure was due to personal reasons and will not impact its operational development [2]. Group 4: Related Transactions - Ruikang's planned acquisition of a 76.01% stake in Zhejiang Hengjiu Medical Equipment for 151 million yuan has drawn scrutiny due to the target company's poor financial performance, with no revenue reported for three consecutive years [6][8]. - The acquisition is part of Ruikang's strategy to expand into the medical device sector, despite Zhejiang Hengjiu's ongoing losses and lack of revenue [9].

证券代码：002589 证券简称：瑞康医药 公告编号：2025-038 瑞康医药集团股份有限公司 关于公司董事、副总裁辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）董事会收到公司董事、副 总裁韩春林先生提交的书面辞职报告。韩春林先生因个人原因决定申请辞去公司 董事、副总裁职务以及公司及子公司的所有其他职务，辞职后将不再担任公司及 控股子公司任何职务。 根据《公司法》《公司章程》相关规定，韩春林先生的辞职不会导致公司董 事人数低于法定人数，不会影响董事会及董事会专门委员会正常运作和公司正常 生产经营。韩春林先生的辞职报告自送达公司董事会之日起生效。公司董事会将 根据《公司章程》等相关规定尽快进行董事补选工作。 公司董事会对韩春林先生在任职期间为公司发展所做出的贡献表示衷心感 谢。 特此公告。 瑞康医药集团股份有限公司 董 事 会 2025 年 7 月 14 日 1 截至本公告披露日，韩春林先生未持有公司股票，不存在未履行的承诺事项。 ...

Core Viewpoint - The simultaneous announcement of a share buyback and the detention of a senior executive at Ruikang Pharmaceutical has raised significant concerns in the capital market, particularly regarding a controversial related-party transaction that occurred six months prior [1]. Group 1: Controversial Acquisition - Ruikang Pharmaceutical announced the acquisition of 76.01% of Zhejiang Hengjiu Medical Equipment for 151 million yuan, despite the target company having zero revenue and a net loss of 6.81 million yuan in the first eight months of 2024 [2]. - The acquisition price represented a nearly 10-fold premium over the target company's net asset value of 18.22 million yuan, with an assessed value of 239.5 million yuan [2]. - The actual controller of the transaction counterpart, Yantai Hengyue, is linked to senior executives including Li Zhe, indicating a typical related-party transaction [2]. Group 2: Executive Detention and Background - Li Zhe, the detained executive, has a financial background with experience at major institutions and a relatively low annual salary of 403,500 yuan, yet he was deeply involved in the controversial acquisition [3]. - Li Zhe controls Yantai Hengyue through Hangzhou Huaheng Investment Management Co., and the acquisition included a three-year profit commitment of 56 million yuan from 2027 to 2029, despite the core product still being in the development stage [3]. Group 3: Financial Performance and Challenges - Ruikang Pharmaceutical has faced a dramatic decline in revenue, dropping from 27.23 billion yuan in 2020 to 7.966 billion yuan in 2024, a decrease of over 70% [4]. - The company has reported cumulative losses of 1.496 billion yuan from 2021 to 2024, with a further 44.75% decline in net profit in the first quarter of 2025 [4]. - Regulatory warnings have been frequent, with the company and its executives being recorded in integrity files for concealing 460 million yuan in related-party capital increases and financial support [4]. Group 4: Market Reactions and Future Outlook - As of June 30, Ruikang Pharmaceutical spent 60.39 million yuan to repurchase 20.44 million shares in an attempt to instill confidence in the market [4]. - Investors are particularly concerned about the connection between Li Zhe's detention and the premium acquisition, the feasibility of the zero-revenue target meeting its profit commitments, and the source of funding for the company's transformation after four consecutive years of losses [4][5].

Group 1 - Liu Zhongliang, former president and party secretary of the Shanyang County People's Hospital, was sentenced to two and a half years in prison for accepting bribes totaling approximately 1.262 million yuan [2][3][4] - The bribes were received from 16 individuals, including a manager from a subsidiary of Ruikang Pharmaceutical, to gain advantages in medical equipment procurement and supply of consumables [2][5][6] - Ruikang Pharmaceutical's subsidiary, Ruikang Pharmaceutical (Shaanxi) Medical Device Co., Ltd., was implicated in the bribery case, although the company denied any knowledge of the alleged bribe [7][8] Group 2 - Ruikang Pharmaceutical is a comprehensive medical service provider listed on the A-share market, with a peak revenue exceeding 35 billion yuan in 2019, but has faced a continuous decline in revenue, reporting around 8 billion yuan in 2024 [7] - The company has experienced a net profit loss for four consecutive years, with a reported loss of 128 million yuan in 2024 [7] - Recently, Ruikang Pharmaceutical's board member and vice president was placed under investigation, indicating potential ongoing issues within the company's management [8]